The United States remains a key contributor to the growth of the Cutaneous Cell Lymphoma Treatment Market, supported by advanced oncology care infrastructure and increasing adoption of innovative therapies. Rising awareness of rare skin lymphomas, growing investment in cancer research, and strong regulatory support for novel drug approvals are driving market expansion. The United...